Silexion Therapeutics Ltd.SLXNNASDAQ
Loading
SLXN Revenue Growth (YoY Quarterly)•+0.00%
Stock Alarm Pro
Growth Metrics
Latest: Q3 2025vs Q2 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
+0.00%
+0.0pp
-82.51%
+4.0pp
-82.51%
+4.0pp
+0.00%
+0.0pp
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -8682.09% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -8682.09% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +17.15% | +851.77% | +506.77% | -86.52% | -82.51% |
| Weighted Average Shares Diluted Growth | +17.15% | +851.77% | +506.77% | -86.52% | -82.51% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -45.56% | -45.53% | +131.74% | +129.58% | +276.22% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +73.10% | +2526.32% | +2318.06% | +3087.93% | -88.75% |
| R&D Expense Growth | +501.31% | -99.93% | -38.61% | +32.90% | -32.95% |
| SG&A Expenses Growth | +2479.03% | -97.32% | +275.80% | +106.37% | -76.42% |
1 / 4